Pancreatic Cancer Research

ResearcherThe University of OsakaActive in the last 2 years

Tsukasa Tanida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4328-7625; OpenAlex author ID A5023698930, A5031314925. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. Prognostic Significance of Number of Liver Metastases in Patients With Advanced Pancreatic Cancer Receiving Nab-paclitaxel Plus Gemcitabine. Co-author DOI 10.21873/cdp.10592↗
  2. Prognostic Significance of ABO Blood Type in Patients with Advanced Pancreatic Cancer Treated with Nab-Paclitaxel Plus Gemcitabine. Co-author DOI 10.1097/mpa.0000000000002515↗
  3. Clinical Significance of Increased Skeletal Muscle Mass During Nab-Paclitaxel Plus Gemcitabine Treatment in Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002269↗
  4. Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer. Co-author DOI 10.1097/md.0000000000029532↗
  5. Optimal Relative Dose Intensity in the First 4 Weeks During Nab-Paclitaxel Plus Gemcitabine for Older Patients With Advanced Pancreatic Cancer in Japan. Co-author DOI 10.1097/mpa.0000000000001942↗
  6. Baseline Factors Predictive of the Receipt of Second-Line Chemotherapy After Nab-Paclitaxel Plus Gemcitabine for Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002013↗
  7. Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000205↗
  8. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells. Co-author DOI 10.3892/ijo.2014.2717↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shusei Tominaga · 6 shared papers, 2022–2026 · strength 1.18
  2. Kiyotsugu Iede · 6 shared papers, 2022–2026 · strength 1.18
  3. Masahiro Tanemura · 2 shared papers, 2015 · strength 0.08
  4. Yuichiro Doki · 2 shared papers, 2015 · strength 0.08
  5. Hidetoshi Eguchi · 2 shared papers, 2015 · strength 0.08
  6. Hirofumi Akita · 2 shared papers, 2015 · strength 0.08
  7. Hiroaki Nagano · 2 shared papers, 2015 · strength 0.08
  8. Eiji Miyoshi · 2 shared papers, 2015 · strength 0.08
  9. Kenta Furukawa · 2 shared papers, 2015 · strength 0.08
  10. Tetsuji Naka · 1 shared paper, 2015 · strength 0.04
  11. Yoshito Tomimaru · 1 shared paper, 2015 · strength 0.04
  12. Shinichiro Shinzaki · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.